Skip to main
CLBT

CLBT Stock Forecast & Price Target

CLBT Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cellebrite DI is a solid investment with a positive outlook. Their strong financial profile, expansion plans, and focus on organic growth and strategic M&A make them a strong player in the digital forensics and investigative analytics industry. While there are risks, they are actively addressing them and are expected to continue growing.

Bears say

Cellebrite DI is facing significant risks in its core public and federal sector customer base, as budget changes and delays, competition, and technological risks could negatively impact its operating results. Additionally, the company's reliance on government and law enforcement agencies for the majority of its revenue exposes it to potential budget cuts and early terminations. Furthermore, the risk of a breach of its solutions, which would result in reputational, monetary, and legal consequences, could also impact future growth and market sentiment. Its current valuation at 7.2x EV/Sales suggests a conservative outlook, but the potential for faster conversions and new revenue drivers from its recent acquisition could serve as medium to long-term catalysts.

CLBT has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cellebrite DI Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cellebrite DI Ltd (CLBT) Forecast

Analysts have given CLBT a Strong Buy based on their latest research and market trends.

According to 5 analysts, CLBT has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cellebrite DI Ltd (CLBT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.